A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI® (chenodiol) tablets (“Ctexli”). Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”) that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”) in the United States (“U.S.”), the European Union (“EU”) and various other countries around the world and for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (“PFIC”) in the U.S., Canada and Japan and for the treatment of PFIC in the EU. We market and commercialize Livmarli in the U.S., Canada and certain countries in Europe through our specialized and focused commercial team.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 521M | 521M | 337M | 186M | 77M | - |
| Net Income | -23M | -23M | -88M | -163M | -136M | -84M |
| EPS | $-0.47 | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 |
| Free Cash Flow | 55M | 55M | 9.3M | -71M | -120M | -133M |
| ROIC | -5.2% | -4.0% | -16.5% | -29.4% | -95.5% | -69.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 1.01 | 1.01 | 1.40 | 1.24 | 0.02 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -22M | -22M | -88M | -109M | -131M | -173M |
| Operating Margin | -4.2% | -4.2% | -26.0% | -58.6% | -170.3% | - |
| ROE | -7.4% | -8.6% | -39.0% | -65.7% | -95.5% | -69.9% |
| Shares Outstanding | 50M | 50M | 48M | 41M | 34M | 30M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0 | N/A | 77M | 186M | 337M | 521M | 521M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 82M | 131M | 107M | 103M | 141M | 186M | 186M |
| SG&A | 23M | 59M | 89M | 146M | 202M | 257M | 257M |
| EBIT | -104M | -173M | -131M | -109M | -88M | -22M | -22M |
| Op. Margin | N/A | N/A | -170.3% | -58.6% | -26.0% | -4.2% | -4.2% |
| Net Income | -103M | -84M | -136M | -163M | -88M | -23M | -23M |
| Net Margin | N/A | N/A | -176.0% | -87.7% | -26.1% | -4.5% | -4.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -60.0% | -69.9% | -95.5% | -29.4% | -16.5% | -4.0% | -5.2% |
| ROE | -60.0% | -69.9% | -95.5% | -65.7% | -39.0% | -8.6% | -7.4% |
| ROA | -42.9% | -28.5% | -38.4% | -25.3% | -13.1% | -3.1% | -2.8% |
| Cash Flow | |||||||
| Op. Cash Flow | -89M | -133M | -120M | -71M | 10M | 56M | 56M |
| Free Cash Flow | -89M | -133M | -120M | -71M | 9.3M | 55M | 55M |
| Owner Earnings | -102M | -156M | -150M | -117M | -62M | -40M | -40M |
| CapEx | 225K | 24K | 278K | 109K | 993K | 954K | 954K |
| Maint. CapEx | 305K | 595K | 3.2M | 11M | 24M | 24M | 24M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 305K | 595K | 3.2M | 11M | 24M | 24M | 24M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 9.6% | 1.7% | 1.7% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 13M | 23M | 27M | 35M | 48M | 71M | 71M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -229M | -154M | -150M | 22M | 36M | -66M | 21M |
| Cash & Equiv. | 142M | 31M | 28M | 286M | 223M | 297M | 297M |
| Long-Term Debt | N/A | N/A | 0 | 306M | 308M | 310M | 310M |
| Debt/Equity | 0.02 | 0.02 | 0.02 | 1.24 | 1.40 | 1.01 | 1.01 |
| Interest Coverage | -311.3 | -9.9 | -8.2 | -7.2 | -6.1 | -1.5 | -1.5 |
| Equity | 172M | 120M | 142M | 249M | 226M | 315M | 315M |
| Total Assets | 241M | 295M | 353M | 647M | 671M | 843M | 843M |
| Total Liabilities | 69M | 174M | 211M | 398M | 445M | 528M | 528M |
| Intangibles | N/A | 19M | 59M | 253M | 250M | 261M | 261M |
| Retained Earnings | -173M | -257M | -393M | -556M | -644M | -668M | -668M |
| Working Capital | 218M | 124M | 125M | 300M | 266M | 344M | 344M |
| Current Assets | 236M | 167M | 190M | 388M | 393M | 550M | 550M |
| Current Liabilities | 18M | 43M | 65M | 87M | 127M | 206M | 206M |
| Per Share Data | |||||||
| EPS | -4.09 | -2.77 | -4.02 | -4.00 | -1.85 | -0.47 | -0.47 |
| Owner EPS | -4.04 | -5.16 | -4.46 | -2.86 | -1.30 | -0.80 | -0.80 |
| Book Value | 6.82 | 3.96 | 4.21 | 6.09 | 4.75 | 6.33 | 6.33 |
| Cash Flow/Share | -3.53 | -4.38 | -3.56 | -1.74 | 0.22 | 1.12 | 0.02 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 25.2M | 30.3M | 33.7M | 40.9M | 47.5M | 49.7M | 49.7M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -205.3 |
| P/FCF | N/A | N/A | N/A | N/A | 211.7 | 71.8 | 87.4 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 2.6 | 4.0 | 4.3 | 4.9 | 8.8 | 12.5 | 15.2 |
| Price/Sales | N/A | N/A | 9.6 | 5.8 | 4.8 | 5.4 | 9.2 |
| FCF Yield | -19.9% | -27.5% | -19.7% | -5.8% | 0.5% | 1.4% | 1.1% |
| Market Cap | 448M | 483M | 610M | 1.2B | 2.0B | 3.9B | 4.8B |
| Avg. Price | 18.64 | 17.23 | 21.89 | 26.67 | 33.85 | 56.61 | 96.49 |
| Year-End Price | 17.76 | 15.93 | 18.08 | 29.96 | 41.56 | 79.26 | 96.49 |
Mirum Pharmaceuticals, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 106.1x vs a median of 71.8x.
Mirum Pharmaceuticals, Inc. (MIRM) has a 5-year average return on invested capital (ROIC) of -43.1%. This is below average and may indicate limited pricing power.
Mirum Pharmaceuticals, Inc. (MIRM) has a market capitalization of $4.8B. It is classified as a mid-cap stock.
Mirum Pharmaceuticals, Inc. (MIRM) does not currently pay a regular dividend.
Mirum Pharmaceuticals, Inc. (MIRM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Mirum Pharmaceuticals, Inc. (MIRM) reported annual revenue of $521 million in its most recent fiscal year, based on SEC EDGAR filings.
Mirum Pharmaceuticals, Inc. (MIRM) has a net profit margin of -4.5%. The company is currently unprofitable.
Mirum Pharmaceuticals, Inc. (MIRM) generated $55 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Mirum Pharmaceuticals, Inc. (MIRM) has a debt-to-equity ratio of 1.01. This indicates moderate leverage.
Mirum Pharmaceuticals, Inc. (MIRM) reported earnings per share (EPS) of $-0.47 in its most recent fiscal year.
Mirum Pharmaceuticals, Inc. (MIRM) has a return on equity (ROE) of -8.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Mirum Pharmaceuticals, Inc. (MIRM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Mirum Pharmaceuticals, Inc. (MIRM) has a book value per share of $6.33, based on its most recent annual SEC filing.